Home » Abbott Gains FDA Clearance for One Cardiac Ablation Catheter, CE Mark for Another
Abbott Gains FDA Clearance for One Cardiac Ablation Catheter, CE Mark for Another
Abbott has received FDA clearance for a new indication for its FlexAbility sensor enabled ablation catheter for ventricular tachycardia (VT) in patients with non-ischemic cardiomyopathy.
The expanded indication for the FlexAbility catheter comes after the company conducted a pre-market trial which showed that 80 percent of 600 study participants were free from VT for at least six months after the procedure.
Abbott has also gained a CE mark for its TactiFlex ablation catheter for common arrhythmias like atrial fibrillation. The Tactiflex catheter has a flexible tip and contact force sensing which is “proven to reduce procedure times and patients’ exposure to radiation” compared to standard power ablation, the company said.
Upcoming Events
-
18Jul
-
21Oct